Figure 6.

Lacidipine induces lumen formation through MLCK inhibition rather than ROCK inhibition. Representative fluorescence images of ML7, a myosin light chain kinase inhibitor (1 μM), which enhances the lumen formation with a similar phenotype of Lacidipine. However, the ROCK inhibitor (GSK429286, 5 μM) did not enhance the lumen formation. n = 4 per condition, data are expressed as mean ± S.E.M, one-way ANOVA followed by Bonferroni’s post hoc test, **** p < 0.0001 as compared to vehicle; scale bar = 100 μm.